Calidi Biotherapeutics earnings were -$27.9M for the trailing 12 months ending Sep 30, 2024, with N/A growth year over year. The latest CLDI earnings report on Sep 30, 2024 announced Q3 2024 earnings of -$5.1M, down 32.1% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, CLDI reported annual earnings of -$29.2M, with 14.9% growth.
Calidi Biotherapeutics Earnings Reports & History FAQ
What were Calidi Biotherapeutics's earnings last quarter?
Calidi Biotherapeutics (NYSEMKT: CLDI) reported Q3 2024 earnings per share (EPS) of -$0.65, up 53.9% year over year. Total CLDI earnings for the quarter were -$5.05 million. In the same quarter last year, Calidi Biotherapeutics's earnings per share (EPS) was -$1.41.
Is Calidi Biotherapeutics profitable or losing money?
As of the last Calidi Biotherapeutics earnings report, Calidi Biotherapeutics is currently losing money. Calidi Biotherapeutics's net profit (also called net income) for the twelve months ending Sep 30, 2024 was -$26.28 million, a 8.59% decrease year over year.
What was CLDI's earnings growth in the past year?
As of Calidi Biotherapeutics's earnings date in Q1 2025, Calidi Biotherapeutics's earnings has grown year over year. CLDI earnings in the past year totalled -$27.95 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.